AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03073148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tangible Boost
Description: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
Study NCT03073148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution.
Study NCT03665610 — intervention group
Intervention type: DRUG
Intervention: ozanimod
Description: ozanimod
Study NCT04106726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soolantra® Ivermectin cream 1%
Description: Apply topically to the face once daily for 84 consecutive days.
Study NCT04106726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin cream 1%
Description: Apply topically to the face once daily for 84 consecutive days.
Study NCT04106726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Ivermectin cream 1%
Description: Apply topically to the face once daily for 84 consecutive days.
Study NCT01067781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat-Labile Enterotoxin of E. coli (LT)
Description: Travelers' Diarrhea Vaccine System
Study NCT01067781 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Travelers' Diarrhea Vaccine System
Study NCT03757728 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haemorrhoidectomy operations
Description: for treatment of symptomatic 2 to 3 degree haemorrhoids
Study NCT00927459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02347878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: use aprepitant 1 hour before lumbar puncture and intrathecal treatment
Study NCT04275466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: necrotic cavity lavage
Description: 1. At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~2. Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~3. 1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~4. The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is >100 mL.~5. Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is >38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure.
Study NCT04222101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: measure insulin, glucose and FGF21 levels in response to oral glucose challenge
Study NCT02675387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
Study NCT02675387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2%Lidocaine
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
Study NCT00109655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic adenovirus (serotype 5) - CG0070
Description: Intravesical administration of CG0070 (in suspension) directly into the bladder
Study NCT03711565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Nasal CPAP using a conventional ventilator
Description: The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
Study NCT02675387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2%Lidocaine
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
Study NCT01795430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT04119661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Max-i-Probe
Description: Using Max-i-Probe as endodontic needle during syringe irrigation
Study NCT01795430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT01795430 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo WB-MRI-guided IMRT
Study NCT01795430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT01795430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT03711565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Nasal CPAP
Description: High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
Study NCT01795430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT01795430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous peripheral blood stem cell or bone marrow transplant
Study NCT01795430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT01795430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Undergo autologous bone marrow transplant
Study NCT00879138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Study NCT00879138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study NCT03589079 — intervention group
Intervention type: GENETIC
Intervention: Sanger and/or Next Generation Sequencing (NGS)
Description: NGS panel, whole exome / genome sequencing (WES/WGS)
Study NCT01804920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-serine
Study NCT01804920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02919800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: MOD-5014, a long-acting modified recombinant Factor VIIa
Study NCT02919800 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MOD-5014 Placebo
Description: Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
Study NCT00477230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ablation System
Description: Single ablation procedure with Endoscopic Ablation System
Study NCT00477230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anti-arrhythmic Drug (AAD) Therapy
Description: Medication as prescribed by physician.
Study NCT00942890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES (EMPI 300PV stimulator) plus standard of care
Description: In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
Study NCT03626155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
Study NCT03626155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Control
Description: Participants will be asked to sit quietly and read during a 50 minute control period
Study NCT00476216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Arixtra with chemotherapy
Description: Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 \& 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy.
Study NCT03971682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP program.
Description: The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
Study NCT03971682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual - TAU
Description: Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
Study NCT03971682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual - TAU
Description: Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
Study NCT01384708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proflavine
Description: 1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
Study NCT03195868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Realief Therapy
Description: Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
Study NCT04274907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral
Study NCT04274907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) Infusion
Study NCT04274907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) Infusion
Study NCT03502655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: Intervention message (first phase)
Description: Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
Study NCT03502655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Comparator: Control message (first phase)
Description: Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
Study NCT03502655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: Intervention message (second phase)
Description: Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
Study NCT03502655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Comparator: Control message (second phase)
Description: Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
Study NCT01579591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: 1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
Study NCT04119661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaviTip
Description: Using NaviTip as endodontic needle during syringe irrigation
Study NCT04280172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural Competence Education
Description: Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
Study NCT04280172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mentoring Education
Description: Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
Study NCT02714686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radio Mass Media Family Planning Campaign
Description: Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
Study NCT01579591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
Study NCT00942890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TMARP standard of care
Description: The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
Study NCT03711682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
Study NCT03977090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection
Description: GB226 3mg/kg, q2w, iv.
Study NCT03977090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
Study NCT00160680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: * Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use
Study NCT01773070 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-450/ritonavir
Description: ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Study NCT01773070 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Study NCT01773070 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-267
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Study NCT02514629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02514629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00708331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 HEMA Hydrophilic Acrylic Intraocular Lens
Description: 2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
Study NCT03309891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: subcutaneous injection (weekly or twice-monthly)
Study NCT03309891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: subcutaneous injection (daily)
Study NCT02514629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Study NCT02514629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Testosterone Undecanoate
Study NCT03287596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI ZTE2 sequence
Description: feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
Study NCT01507896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor IX
Description: Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
Study NCT02179684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baby-sitter surgery N. fascialis
Study NCT02179684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment and follow-up
Description: Patient´s with Bells´palasy are treated with conventional treatment and follow-up
Study NCT03316079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy techniques
Description: Respiratory manual CPT
Study NCT03316079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
Study NCT03154879 — intervention group
Intervention type: DEVICE
Intervention: Amplitude integrated electroencephalography
Description: Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
Study NCT01786811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person.
Study NCT01040325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TD Vaccine System
Description: TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
Study NCT03711682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Flour
Description: Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
Study NCT00654810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Intermittent treadmill walking to near maximal claudication pain three days per week
Study NCT01562210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID.
Study NCT01562210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
Study NCT01562210 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.